The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
Regimen E will evaluate the safety and efficacy of a single study drug, SLS-005 (Trehalose injection, 90.5 mg/mL for intravenous infusion) in participants with ALS.
For SLS-005 Trehalose clinical study queries, please contact: [email protected]
For additional information, please contact:
Healey Center for ALS at Massachusetts General Hospital
Phone: 833-425-8257 (HALT ALS)
Email: [email protected]
ClinicalTrials.gov Identifier: NCT05136885